Ariad Pharmaceuticals, like many biotech firms, once pursued drugs only for the largest markets but now is testing a drug, AP23573, aimed at a rare form of sarcoma diagnosed in only 12,000 to 13,000 patients a year. Other boutique firms focusing on rare disease are finding the cause may be narrowed to a single gene and the results can be successful and profitable when few other remedies exist.

Full Story:

Related Summaries